Sugi Predict

Sugi Predict / Compounds / SCHEMBL19948646

SCHEMBL19948646

SCHEMBL19948646

Cc1cc2[nH]ncc2c(Br)c1C

nearest known ligand 0.47

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 6/20 0.47
▸ TDO2 P48775 3/20 0.47
▸ NOS1 P29475 3/20 0.41
▸ AXL P30530 2/20 0.41
▸ METAP2 P50579 8/20 0.41
▸ DYRK1A Q13627 2/20 0.37
▸ CSNK2A1 P68400 1/20 0.37
▸ CYP1A2 P05177 2/20 0.37
▸ PTPN6 P29350 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30410207 1.00 IDO1 (0.47) IDO1TDO2NOS1AXLMETAP2
SCHEMBL28499459 0.88 IDO1 (0.50) IDO1TDO2NOS1AXLMETAP2
SCHEMBL21196238 0.86 IDO1 (0.48) IDO1TDO2NOS1AXLMETAP2
SCHEMBL30641259 0.83 TDO2 (0.43) IDO1TDO2NOS1AXLMETAP2
SCHEMBL21379129 0.83 TDO2 (0.43) IDO1TDO2NOS1AXLMETAP2
SCHEMBL29937471 0.83 IDO1 (0.47) IDO1TDO2NOS1AXLMETAP2
SCHEMBL21196262 0.83 IDO1 (0.47) IDO1TDO2NOS1AXLMETAP2
SCHEMBL16646932 0.81 IDO1 (0.50) IDO1TDO2NOS1AXLMETAP2
SCHEMBL31527502 0.81 IDO1 (0.44) IDO1TDO2NOS1AXLMETAP2
SCHEMBL21195949 0.81 IDO1 (0.44) IDO1TDO2NOS1AXLMETAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260060961-A1 SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS JAZZ PHARMACEUTICALS IRELAND LTD (IE) 2026-03-05 — — US disclosed
US-20260015350-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS MIRATI THERAPEUTICS INC (US) 2026-01-15 — — US disclosed
EP-4581024-A1 SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS Jazz Pharmaceuticals Ireland Limited (IE) 2025-07-09 — — EP disclosed
WO-2025076523-A1 RAS INHIBITORS AND METHODS OF USE THEREOF KESTREL THERAPEUTICS, INC. (US) 2025-04-10 — — WO disclosed
US-20240317721-A1 PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN NOVARTIS AG (CH) 2024-09-26 — — US disclosed
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-18 — — US disclosed
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-18 — — US disclosed
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-18 — — US disclosed
CN-111989321-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2024-05-14 — — CN disclosed
EP-4359081-A1 PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN Novartis AG (CH) 2024-05-01 — — EP disclosed
EP-3710439-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2020-09-23 — — EP disclosed
US-20200262837-A1 KRAS G12C INHIBITORS ARRAY BIOPHARMA INC. 2020-08-20 — — US disclosed
US-10689377-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2020-06-23 — — US disclosed
US-10662204-B2 Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents PFIZER INC. (US) 2020-05-26 — — US disclosed
US-10633381-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2020-04-28 — — US disclosed
US-20190233440-A1 Substituted Quinazoline and Pyridopyrimidine Derivatives Useful as Anticancer Agents PFIZER INC. (US) 2019-08-01 — — US disclosed
US-20190144444-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2019-05-16 — — US disclosed
US-10125134-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2018-11-13 — — US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190144444-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS IDO1 4640/4885TDO2 4833/4885NOS1 4612/4885
US-10633381-B2 KRas G12C inhibitors KRAS, NRAS, HRAS IDO1 4640/4885TDO2 4833/4885NOS1 4612/4885
US-20200262837-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS IDO1 4640/4885TDO2 4833/4885NOS1 4612/4885
US-20260060961-A1 SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS KRAS, NRAS, HRAS IDO1 4151/4885TDO2 3967/4885NOS1 3015/4885
US-10125134-B2 KRas G12C inhibitors KRAS, NRAS, HRAS IDO1 4640/4885TDO2 4833/4885NOS1 4612/4885
US-20240317721-A1 PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN KRAS, NRAS, APC IDO1 4669/4885TDO2 4562/4885NOS1 4557/4885
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT KRAS, NRAS, HRAS IDO1 4773/4885TDO2 4805/4885NOS1 4548/4885
US-10689377-B2 KRas G12C inhibitors KRAS, NRAS, HRAS IDO1 4640/4885TDO2 4833/4885NOS1 4612/4885
US-10662204-B2 Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents DPYD, PDXK, TYMP IDO1 2232/4885TDO2 1701/4885NOS1 3030/4885
US-20190233440-A1 Substituted Quinazoline and Pyridopyrimidine Derivatives Useful as Anticancer Agents DPYD, TYMP, TOP2A IDO1 2468/4885TDO2 1981/4885NOS1 3221/4885
US-20180072723-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS IDO1 4640/4885TDO2 4833/4885NOS1 4612/4885
US-20260015350-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS KRAS, NRAS, HRAS IDO1 4243/4885TDO2 4596/4885NOS1 4037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.